If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> EMJ Oncology 2019 Suppl 2 • europeanmedical-journal.com<br /> INSIDE<br /> BCG-Unresponsive Bladder<br /> Cancer: New Frontiers in<br /> the Treatment Landscape<br /> BCG-Unresponsive Bladder Cancer: New Frontiers in<br /> the Treatment Landscape<br /> This meeting took place on 28th September 2019, as part of the<br /> Ferring-organised Meet-The-Expert symposium at the European<br /> Society of Medical Oncology (ESMO) Congress in Barcelona, Spain<br /> Chairperson: Juan Palou Redorta,1<br /> Speakers: Shahrokh Shariat,2-8 Marek Babjuk,9 Thomas Powles10<br /> 1. Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain<br /> 2. Department of Urology, Comprehensive Cancer Center, Medical University of<br /> Vienna, Vienna, Austria<br /> 3. Department of Urology, Weill Cornell Medical College, New York City, New York,<br /> USA<br /> 4. Department of Urology, Univers<a title="EMJ Oncol. Suppl 2 2019 page 1" href="http://viewer.zmags.com/publication/2a52c2a8?page=1"> ONCOLOGY EMJ Oncology 2019 Suppl 2 • europeanmedi</a> <a title="EMJ Oncol. Suppl 2 2019 page 2" href="http://viewer.zmags.com/publication/2a52c2a8?page=2"> BCG-Unresponsive Bladder Cancer: New Frontiers in</a> <a title="EMJ Oncol. Suppl 2 2019 page 3" href="http://viewer.zmags.com/publication/2a52c2a8?page=3"> emphasised the need to clearly define refractory d</a> <a title="EMJ Oncol. Suppl 2 2019 page 4" href="http://viewer.zmags.com/publication/2a52c2a8?page=4"> at 6 months. BCG relapse is when high-grade disea</a> <a title="EMJ Oncol. Suppl 2 2019 page 5" href="http://viewer.zmags.com/publication/2a52c2a8?page=5"> respectively. While these appear suboptimal, </a> <a title="EMJ Oncol. Suppl 2 2019 page 6" href="http://viewer.zmags.com/publication/2a52c2a8?page=6"> Moreover, a new drug delivery system for in</a> <a title="EMJ Oncol. Suppl 2 2019 page 7" href="http://viewer.zmags.com/publication/2a52c2a8?page=7"> response or RB1 genomic alterations, a PD- </a> <a title="EMJ Oncol. Suppl 2 2019 page 8" href="http://viewer.zmags.com/publication/2a52c2a8?page=8"> Curr Opin Oncol. 2015;27(3):191-200. 20. Tomasze</a> <a title="EMJ Oncol. Suppl 2 2019 page 9" href="http://viewer.zmags.com/publication/2a52c2a8?page=9"> 2018;36(34):3353-60. </a>